Griesser H
Department of Oncologic Pathology, Ontario Cancer Institute, Toronto, Canada.
Virchows Arch. 1995;426(4):323-38. doi: 10.1007/BF00191340.
The diversity of the T cell receptor (TCR) repertoire is established for individual T lymphocytes by developmentally regulated gene rearrangements and shaped by predominantly intrathymic selection procedures. TCR gene probes in Southern blot experiments and TCR primers for the polymerase chain reaction (PCR) help to distinguish polyclonal from abnormal clonal T cell proliferations and to monitor clonal disease after treatment. Rearrangement studies can identify the lineage and developmental stage of a lymphocyte clone. Cross-lineage rearrangements, false positive or negative results are rarely misleading when morphology and immunophenotypical findings are considered. Rearrangement studies, however, have not contributed significantly to the comprehension of lymphomagenesis. Analyses of characteristic chromosomal translocations in T cell leukaemias and lymphomas may provide further insight into the mechanisms of malignant transformation. Transcription factors are often involved and sometimes abnormally transcribed, which may alter the physiological intracellular signalling in T cells. Interphase cytogenetic analysis by chromosomal fluorescence in situ hybridization (FISH) has become a new tool in the search for transformed T cells carrying specific translocations. Archival biopsy material is now accessible for PCR rearrangement studies and FISH cytogenetics. This adds another dimension to the diagnosis, disease monitoring and biological understanding of malignant T cell lymphomas and leukaemias.
通过发育调控的基因重排,个体T淋巴细胞建立了T细胞受体(TCR)库的多样性,并主要由胸腺内选择程序塑造。Southern印迹实验中的TCR基因探针和聚合酶链反应(PCR)的TCR引物有助于区分多克隆T细胞增殖与异常克隆性T细胞增殖,并在治疗后监测克隆性疾病。重排研究可以确定淋巴细胞克隆的谱系和发育阶段。当考虑形态学和免疫表型结果时,跨谱系重排、假阳性或假阴性结果很少会产生误导。然而,重排研究对淋巴瘤发生机制的理解贡献不大。对T细胞白血病和淋巴瘤中特征性染色体易位的分析可能会进一步深入了解恶性转化机制。转录因子经常参与其中,有时会异常转录,这可能会改变T细胞中的生理细胞内信号传导。通过染色体荧光原位杂交(FISH)进行的间期细胞遗传学分析已成为寻找携带特定易位的转化T细胞的新工具。现在可以获取存档活检材料用于PCR重排研究和FISH细胞遗传学分析。这为恶性T细胞淋巴瘤和白血病的诊断、疾病监测及生物学理解增添了新的维度。